Etiology of Parkinson’s disease

The etiology of Parkinson’s disease (PD) has long been thought to involve both genetic and environmental factors, but until recently there has been no direct evidence to support either one as a causative factor. However, in the past 8 years six different genes have been identified as causing familial PD. Together, they support the notion that common pathogenetic mechanisms exist across the etiologic spectrum of PD. Specifically, mutations in α-synuclein, parkin, UCHL1, DJ1, PINK1, and LRRK2 cause PD, with a Mendelian pattern of inheritance. DJ1 and PINK1 are mitochondrial proteins and overexpression of α-synuclein and parkin induce mitochondrial defects. These same proteins are involved in the response to oxidative stress and affect proteasomal function. In contrast, few environmental factors have been characterized. Nevertheless, those toxins that have been demonstrated to have the ability to cause nigrostriatal cell death appear to interact by interfering with mitochondrial function, inducing oxidative stress, and modifying proteasomal function. Therefore, common themes are beginning to emerge in the etiopathogenesis of PD. This bodes well for research focused on the development of treatments that will modify the course of PD.

[1]  M. Feany,et al.  Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.

[2]  Pietro Cortelli,et al.  Homozygous PINK1 C‐terminus mutation causing early‐onset parkinsonism , 2004, Annals of neurology.

[3]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[4]  C. Marsden,et al.  Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. , 1992, Annals of neurology.

[5]  C. Marsden,et al.  Mitochondrial function in Parkinson's disease , 1992, Annals of neurology.

[6]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[7]  A. Hofman,et al.  Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.

[8]  E. Love,et al.  Parkinson's disease and exposure to agricultural work and pesticide chemicals , 1992, Neurology.

[9]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[10]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[11]  M. Graeber,et al.  Parkinson disease: analysis of mitochondrial DNA in monozygotic twins , 2000, Neurogenetics.

[12]  C. Ross,et al.  Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  Nicholas W. Wood,et al.  The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease , 1999, Neuroscience Letters.

[14]  A. Ridley,et al.  Rho family proteins: coordinating cell responses. , 2001, Trends in cell biology.

[15]  D. Graham,et al.  The role of the environment in Parkinson's disease. , 1996, Environmental health perspectives.

[16]  D. Hernandez,et al.  alpha-Synuclein gene haplotypes are associated with Parkinson's disease. , 2001, Human molecular genetics.

[17]  W. Sweet,et al.  Diseases of the nervous system. , 1956, Annual review of medicine.

[18]  Matthew J. Farrer,et al.  α-synuclein gene haplotypes are associated with Parkinson’s disease , 2001 .

[19]  C. Ross,et al.  α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.

[20]  R. Capaldi,et al.  Subunit specific monoclonal antibodies show different steady-state levels of various cytochrome-c oxidase subunits in chronic progressive external ophthalmoplegia. , 1996, Biochimica et biophysica acta.

[21]  J. Nutt,et al.  Increased risk of Parkinson's disease in parents and siblings of patients , 1994, Annals of neurology.

[22]  R. Peñalver Manganese poisoning. , 1956, Industrial medicine & surgery.

[23]  D W Dickson,et al.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.

[24]  J. Haines,et al.  Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. , 2003, American journal of human genetics.

[25]  Matthew J. Farrer,et al.  Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplications , 2004 .

[26]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[27]  J. Bloomquist,et al.  Selective effects of insecticides on nigrostriatal dopaminergic nerve pathways. , 2002, Neurotoxicology.

[28]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[29]  Jean-François Deleuze,et al.  Complex relationship between Parkin mutations and Parkinson disease. , 2002, American journal of medical genetics.

[30]  S. Tsuji,et al.  Familial juvenile parkinsonism , 1994, Neurology.

[31]  O. Axelson,et al.  Nutritional and occupational factors influencing the risk of Parkinson's disease: A case‐control study in southeastern Sweden , 1999, Movement disorders : official journal of the Movement Disorder Society.

[32]  J. Parks,et al.  Abnormalities of the electron transport chain in idiopathic parkinson's disease , 1989, Annals of neurology.

[33]  P. Lockhart,et al.  Functional association of the parkin gene promoter with idiopathic Parkinson's disease. , 2002, Human molecular genetics.

[34]  Y. Yamamura,et al.  Paralysis agitans of early onset with marked diurnal fluctuation of symptoms , 1973, Neurology.

[35]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[36]  I. Fearnley,et al.  The Phosphorylation of Subunits of Complex I from Bovine Heart Mitochondria* , 2004, Journal of Biological Chemistry.

[37]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[38]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[39]  Y. Agid,et al.  A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. , 1999, Human molecular genetics.

[40]  H. Happe,et al.  High‐Affinity Choline Transport Sites: Use of [3H]Hemicholinium‐3 as a Quantitative Marker , 1993, Journal of neurochemistry.

[41]  D. Hernandez,et al.  The dardarin G2019S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases , 2005, Neuroscience Letters.

[42]  V. Uversky,et al.  The Herbicide Paraquat Causes Up-regulation and Aggregation of α-Synuclein in Mice , 2002, The Journal of Biological Chemistry.

[43]  T. Ozawa,et al.  Point mutations of mitochondrial genome in Parkinson's disease. , 1995, Brain research. Molecular brain research.

[44]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[45]  S. Lewis,et al.  Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD , 2005, Annals of neurology.

[46]  S. Melquist,et al.  LRRK2 mutations are not common in Alzheimer's disease , 2005, Mechanisms of Ageing and Development.

[47]  J. Pittman,et al.  Immunohistochemical Changes in the Mouse Striatum Induced by the Pyrethroid Insecticide Permethrin , 2003, International journal of toxicology.

[48]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[49]  J. Jankovic,et al.  Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation , 2005, Annals of neurology.

[50]  H. Payami,et al.  Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation , 2005, Movement disorders : official journal of the Movement Disorder Society.

[51]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[52]  R. Aggeler,et al.  Focused proteomics: Monoclonal antibody‐based isolation of the oxidative phosphorylation machinery and detection of phosphoproteins using a fluorescent phosphoprotein gel stain , 2004, Electrophoresis.

[53]  P. Allen,et al.  Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle , 1995, Neurology.

[54]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[55]  K. Tipton,et al.  Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.

[56]  M. Tsuda,et al.  Deltamethrin, a Pyrethroid Insecticide, Is a Potent Inducer for the Activity-Dependent Gene Expression of Brain-Derived Neurotrophic Factor in Neurons , 2006, Journal of Pharmacology and Experimental Therapeutics.

[57]  R. Uitti,et al.  Neurological disorders and services in Saskatchewan--a report based on provincial health care records. , 1988, Neuroepidemiology.

[58]  M Behari,et al.  Risk factors of Parkinson's disease in Indian patients , 2001, Journal of the Neurological Sciences.

[59]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[60]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[61]  Hreinn Stefánsson,et al.  A susceptibility gene for late‐onset idiopathic Parkinson's disease , 2002, Annals of neurology.

[62]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[63]  R. Uitti,et al.  Early Onset Parkinson's Disease in Saskatchewan - Environmental Considerations for Etiology , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[64]  G. Wooten,et al.  Maternal inheritance in Parkinson's disease , 1997, Annals of neurology.

[65]  M. Farrer,et al.  Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease. , 2005, Biochemical Society transactions.

[66]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[67]  Peter T. Lansbury,et al.  Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.

[68]  Jean Féger,et al.  Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe , 2003, Journal of neurochemistry.

[69]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[71]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[72]  B. Crain,et al.  Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. , 1993, Genomics.

[73]  M. Graeber,et al.  Absence of the mitochondrial A7237T mutation in Parkinson's disease. , 1995, Biochemical and biophysical research communications.

[74]  I. Kopin,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. , 1985, European journal of pharmacology.

[75]  C. Marsden,et al.  Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.

[76]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[77]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[78]  G. Campanella,et al.  Ecogenetics of Parkinson's Disease: Prevalence and Environmental Aspects in Rural Areas , 1987, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[79]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[80]  D. Middleton,et al.  mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish , 2003, Experimental Gerontology.

[81]  M. Müftüoğlu,et al.  Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations , 2004, Movement disorders : official journal of the Movement Disorder Society.

[82]  J. Haines,et al.  Complete genomic screen in Parkinson disease: evidence for multiple genes. , 2001, JAMA.

[83]  P. Cohen,et al.  The origins of protein phosphorylation , 2002, Nature Cell Biology.

[84]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  E. Love,et al.  Parkinson's Disease and Exposure to Rural Environmental Factors: A Population Based Case-Control Study , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[86]  C. Marsden,et al.  Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.

[87]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .

[88]  E. Hirsch,et al.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.

[89]  V. Uversky,et al.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. , 2002, The Journal of biological chemistry.

[90]  Bryan L Roth,et al.  Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons* , 2003, Journal of Biological Chemistry.

[91]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[92]  K. Ohno,et al.  Distinct clustering of point mutations in mitochondrial DNA among patients with mitochondrial encephalomyopathies and with Parkinson's disease. , 1991, Biochemical and biophysical research communications.

[93]  M. Feany,et al.  α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.

[94]  A. Schapira,et al.  Mitochondrial DNA analysis in Parkinson's disease , 1990, Movement disorders : official journal of the Movement Disorder Society.

[95]  Yusuke Nakamura,et al.  Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway , 2001, Oncogene.

[96]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[97]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[98]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[99]  J. Growdon,et al.  Genome-wide scan for Parkinson's disease: the GenePD Study. , 2001, Neurology.

[100]  J. Jankovic Searching for a relationship between manganese and welding and Parkinson’s disease , 2005, Neurology.

[101]  Salil K. Das,et al.  Cigarette Smoking and Parkinson's Disease , 2007 .

[102]  C. Marsden,et al.  A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.

[103]  A. Mosley,et al.  A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations , 2005, Neurology.

[104]  M. Farrer,et al.  Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. , 2004, Annals of neurology.

[105]  M. Beal,et al.  Sequence analysis of the entire mitochondrial genome in Parkinson's disease. , 2002, Biochemical and biophysical research communications.

[106]  J. Trojanowski,et al.  Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. , 2002, The Journal of biological chemistry.

[107]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[108]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[109]  R. Marconi,et al.  Environmental and genetic risk factors in Parkinson's disease: A case–control study in southern italy , 1996, Movement disorders : official journal of the Movement Disorder Society.

[110]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[111]  K. Marder,et al.  Risk of Parkinson's disease among first-degree relatives , 1996, Neurology.

[112]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[113]  D B Calne,et al.  Progression after chronic manganese exposure , 1993, Neurology.

[114]  L. Fleming,et al.  Parkinson's disease and brain levels of organochlorine pesticides , 1994, Annals of neurology.

[115]  Georg Auburger,et al.  The ubiquitin pathway in Parkinson's disease , 1998, Nature.

[116]  M. Farrer,et al.  Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. , 1999, Neuroreport.

[117]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Karl Herholz,et al.  Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. , 2005, Archives of neurology.

[119]  Yi Zhao,et al.  Alpha synuclein promoter and risk of Parkinson's disease: microsatellite and allelic size variability , 2003, Neuroscience Letters.

[120]  E. Hirsch,et al.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease , 1994, Neuroscience Letters.

[121]  A. Bentivoglio,et al.  PINK1 mutations are associated with sporadic early‐onset parkinsonism , 2004, Annals of neurology.

[122]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[123]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[124]  D. Sulzer,et al.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. , 2000, Neuron.

[125]  M. Farrer,et al.  Pathophysiology, pleotrophy and paradigm shifts: genetic lessons from Parkinson's disease , 2005 .

[126]  S. Tabrizi,et al.  Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. , 2000, Human molecular genetics.

[127]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[128]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[129]  G. Miller,et al.  Pyrethroid pesticide-induced alterations in dopamine transporter function. , 2006, Toxicology and applied pharmacology.

[130]  H. Reichmann,et al.  Novel mitochondrial DNA mutations in Parkinson's disease , 2002, Journal of Neural Transmission.

[131]  Nobutaka Hattori,et al.  Novel PINK1 mutations in early‐onset parkinsonism , 2004, Annals of neurology.

[132]  N. Shimizu,et al.  Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals , 1998, Annals of neurology.

[133]  P. Vieregge,et al.  Increased Risk of Parkinson's Disease in Relatives of Patients , 1995, Annals of neurology.

[134]  Wayne F. Patton,et al.  Characterization of dynamic and steady‐state protein phosphorylation using a fluorescent phosphoprotein gel stain and mass spectrometry , 2004, Electrophoresis.

[135]  T. Hunter,et al.  Signaling—2000 and Beyond , 2000, Cell.

[136]  G. Meco,et al.  Familial Parkinson’s Disease: A Clinical Genetic Analysis , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[137]  A A Schäffer,et al.  Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. , 1997, American journal of human genetics.

[138]  R. Capaldi,et al.  Mammalian cytochrome-c oxidase: characterization of enzyme and immunological detection of subunits in tissue extracts and whole cells. , 1995, Methods in enzymology.

[139]  Robert Hill,et al.  Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease , 1995, Annals of neurology.

[140]  Sarah J. Tabrizi,et al.  Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .

[141]  Paola Piccini,et al.  The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.

[142]  A. Singleton,et al.  alpha-Synuclein locus triplication causes Parkinson's disease. , 2003, Science.

[143]  E. Hirsch,et al.  FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. , 1999, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[144]  Wayne F. Patton,et al.  Analysis of Steady-state Protein Phosphorylation in Mitochondria Using a Novel Fluorescent Phosphosensor Dye* , 2003, Journal of Biological Chemistry.

[145]  T. Dawson,et al.  Response to Comment on "S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function" , 2005, Science.

[146]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[147]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[148]  A. Seidler,et al.  Possible environmental, occupational, and other etiologic factors for Parkinson's disease , 1996, Neurology.